RxDoctor Payments Data

Myunghae Choi, MD

Cardiovascular Disease · Los Angeles, CANPI 1023117413

Payments from drug & device makers

$1,561in general payments, 2019–2025

Across 41 payments — averaging $38.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$512
  • Boston Scientific$190
  • Penumbra, Inc.$149
  • Novartis$109
  • Johnson & Johnson$106
  • Alnylam Pharmaceuticals Inc.$73
  • plus $423 from 10 others

What the payments were for

  • Food & beverage$1,54799%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,561 in reported general payments places this provider in the 40th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$174,994
Medicare patients
330
Services billed
1,515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban127$105,700
EliquisApixaban89$75,808
EntrestoSacubitril/Valsartan73$74,698
JardianceEmpagliflozin50$42,480
BrilintaTicagrelor25$16,217
Digoxin98$2,201
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide65$1,160
Doxazosin Mesylate94$1,011
Rosuvastatin Calcium70$846
Losartan Potassium79$807
Valsartan21$629
Amlodipine Besylate156$478
Nifedipine ErNifedipine17$476
Atorvastatin Calcium109$451
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide34$412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$106$105,700127 claims
PfizerEliquis$30$75,80889 claims
NovartisEntresto$109$74,69873 claims
AstraZenecaBrilinta$35$16,21725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →